Despite SBRT to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.
SCIMITAR is the first phase 2 trial testing the efficacy of stereotactic body radiation therapy (SBRT) targeting the prostate fossa after radical prostatectomy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback